The Tax Court Offers a Mixed Bag in the Mylan Case

Published date11 May 2021
Subject MatterFDA,Internal Revenue Code (IRC),Mylan Pharmaceuticals,Patent Litigation,Generic Drugs,FDA Approval,Tax Court,Abbreviated New Drug Application (ANDA),Prescription Drugs
AuthorDavid Schneider,Scott Rabinowitz
Law FirmSkadden, Arps, Slate, Meagher & Flom LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT